Skip to Content

LY22-02a

Main Content

Efficacy and safety of CD19 directed CAR T-cell therapy for central nervous system lymphoma.

Study #: LY22-02a

Study Status: Manuscript Preparation

Presentation(s)

2024, Tandem (Oral)